Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Payables (2021 - 2025)

Historic Payables for Verrica Pharmaceuticals (VRCA) over the last 5 years, with Q3 2025 value amounting to $1.6 million.

  • Verrica Pharmaceuticals' Payables rose 6407.87% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 6407.87%. This contributed to the annual value of $1.9 million for FY2024, which is 2305.19% down from last year.
  • Verrica Pharmaceuticals' Payables amounted to $1.6 million in Q3 2025, which was up 6407.87% from $2.3 million recorded in Q2 2025.
  • In the past 5 years, Verrica Pharmaceuticals' Payables registered a high of $43.0 million during Q2 2022, and its lowest value of $137000.0 during Q3 2022.
  • In the last 5 years, Verrica Pharmaceuticals' Payables had a median value of $2.1 million in 2023 and averaged $14.3 million.
  • Per our database at Business Quant, Verrica Pharmaceuticals' Payables tumbled by 9967.58% in 2022 and then skyrocketed by 130510.95% in 2023.
  • Verrica Pharmaceuticals' Payables (Quarter) stood at $42.5 million in 2021, then crashed by 98.81% to $507000.0 in 2022, then soared by 386.0% to $2.5 million in 2023, then fell by 23.05% to $1.9 million in 2024, then fell by 16.4% to $1.6 million in 2025.
  • Its Payables was $1.6 million in Q3 2025, compared to $2.3 million in Q2 2025 and $1.4 million in Q1 2025.